leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 01:38:46 - browse：2

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Why doctors need education on FDA device approval process

leisure time

WSS

Research misconduct: Proposed new rules face resistance

NIH director takes cautious approach to Biden drug pricing priority

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Independent physicians launch a new lobbying group

FDA clears AI tool for detecting skin cancer

Dewpoint Therapeutics lays off staff after losing partnerships

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Wildfire pollution widens asthma inequities on Long Island

Peter Hotez and the public health issue of online harassment

‘Oppenheimer’ and the risks of AI in health care

Moonlake's readout produced a cash windfall. Risks remain

Trump indictment: Who are the 'co

Activists slam private health insurers over coverage restrictions

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Walensky prepares to leave CDC — and Congress — behind

Biotech venture capitalists face new demands from investors

explore

Infectious disease expert Jeanne Marrazzo assumes Fauci role

FDA clears AI tool for detecting skin cancer

Independent physicians launch a new lobbying group

Amazon expands telehealth clinic nationwide

Dewpoint Therapeutics lays off staff after losing partnerships

My yearlong odyssey to get my son’s ADHD medication covered

leisure time

leisure time

leisure time

focus